Genomma Lab Internacional Sab De Cv Class B · BMV:LAB/B
Genomma Lab Internacional Sab De Cv Class B — Genomma Lab Intl Sab Ord — Q1 2025 Earnings Presentation
58 slides from Genomma Lab Internacional Sab De Cv Class B's earnings presentation, May 2, 2025
Slide 1: Genomma Lab Internacional Investor Relations
Genomma Lab.°® Internacional GENOMMA LAB INVESTOR RELATIONS
Slide 2: Forward-looking statements
This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limit
Slide 3: About Genomma Lab
Slide 4: About Genomma Lab
ABOUT GENOMMA LAB GENOMMA LAB pevetops, MANUFACTURES AND MARKETS A PORTFOLIO OF 60 PREMIUM BRANDED PRODUCTS FOR MASS CONSUMPTION, MANY OF WHICH ARE LEADERS IN THEIR CATEGORIES BUSINESS UNITS REGIONS 42% 48% 52% 48% PR MEXICO PC + oTc BEVERAGES 5 10% us
Slide 5: Healthy Product Mix
HEALTHY PRODUCT MIX OVER-THE-COUNTER 52% OF TOTAL SALES COUGH & COLD ANALGESICS DERMA OTC INFANT NUTRITION (Novamir Novamil
Slide 6: Healthy Product Mix: Personal Care + Beverages
HAIRCARE HEALTHY PRODUCT MIX PERSONAL CARE + BEVERAGES ISOTONIC BEVERAGES BLADES & RAZORS OTHER SKINCARE
Slide 7: Proven Track Record
Slide 8: Net Sales and EBITDA in MXN million
Net Sales in MXN million EBITDA in MXN million net of discontinued operation effects
Slide 9: Maintaining Gross Margin with Productivity
MAINTAINING GROSS MARGIN WITH PRODUCTIVITY +5.9 pp 5.3% 12.8% Q4 2022 Q12023 Q@2 2023 Q3 2023 Q42023 @12024 Q2 2024 Q3 2024 Q42024 Q12025
Slide 10: Net of discontinued operation effects
Net of discontinued operation effects
Slide 11: $2.1 $1.9 $1.7 $1.5 $1.3 $1.1 $0.9 $0.7 $0.5 0
$2.1 0 $1.9 0 $1.7 0 $1.5 0 $1.3 0 $1.1 0 $0.9 0 $0.7 0 $0.5 0
Slide 12: Free Cash Flow and Dividend per Share
Free Cash Flow in MXN million, Dividend per Share in MXN
Slide 13: 17. 0% 16. 0% 15. 0% 14. 0% 13. 0% 12. 0% 11. 0%
17. 0% 16. 0% 15. 0% 14. 0% 13. 0% 12. 0% 11. 0% 10. 0%
Slide 14: Strategy
Slide 15: MXN 1,800 M
MXN 1,800 M 180 0 1600 160 0 140 0 1200 120 0 100 0 800 800 MXN 1,018 M 600 57% of progress 400 400 200 0 0 2022 2023 2024 2025 2026 2027
Slide 16: Capital Allocation Priorities
CAPITAL ALLOCATION PRIORITIES 1. INVEST IN THE CORE BUSINESS GROWTH PROJECTS 2. DIVIDENDS & BUYBACKS TOTAL SHAREHOLDER RETURN 7 } 3. BOLT-ON M&A STRENGTHEN CORE CATEGORIES
Slide 17: 2025: Investing in Future Sales Growth
2025: INVESTING IN FUTURE SALES GROWTH o FF W N 10 Suerox Skincare Haircare [o} Kes Infant nutrition New categories Channels Digital In-store as media Clients Focus on distribution, int. expansion & entering new a segment Asepxia & Cicatricure relaunch Tio Nacho repositioning, Vanart relaunch & int.
Slide 18: A Strong Business Model
Slide 19: Innovation, go-to-market and core capabilities
INNOVATION ROBUST GO-TO-MARKET PROVEN SUPERIOR INNOVATION CAPABILITIES | +300K POINTS OF SALE MULTICHANNEL DISTRIBUTION ESG COMPREHENSIVE i CORE =t, COMMUNICATION & MARKETING “Rh” MSCI ESG RATING = CAPABILITIES #1 TV ADVERTISERS IN LATAM DIVERSIFIED MARKETING STRATEGY MANUFACTURING & SUPPLY STRONG C
Slide 20: Superior Product Innovation
Superior Product Innovation
Slide 21: Superior Product Innovation
Superior Product Innovation Masstige Affordable Luxury Hi-quality Performance
Slide 22: Superior Product Innovation
Superior Product Innovation Recycled Royal Jelly Shampoo Healthy Hair, Healthy Planet Eco-friendly Recycled Conscious communication 100% 100% recycled sustainable and recyclable packaging PETE bottle Recycling meeting points High quality ingredients
Slide 23: Asepxia Relaunch
ASEPXIA RELAUNCH PRODUCT EXECUTION v Expanded from facial to full-body use V Shifted from acne treatment to daily care V Reformulated: hydrating serum + salicylic acid Y¥ Moved from pharmacy to general soap aisle Vv Priced below category leader Vv Expanded shelf presence
Slide 24: Robust Go-to-Market: Traditional Channel
ROBUST GO-TO-MARKET TRADITIONAL CHANNEL 38% OF SALES (Mexico) REACHING UNATTENDED COMMUNITIES ACCESSIBLE PRODUCT FORMATS OWN FLEET AND EXCLUSIVE SALES FORCE LEVERAGING SUEROX ¢ Independent pharmacies * Mom & pop stores * Wholesale pharma & grocery distributors
Slide 25: Robust Go-to-Market: Modern Channel
ROBUST GO-TO-MARKET MODERN CHANNEL 62% OF SALES (Mexico) DIVERSIFIED CLIENT BASE INCREASED DIRECT DISTRIBUTION EFFICIENT DELIVERIES * Supermarkets Department stores Pharmacy chains * Convenience stores E-commerce
Slide 26: Comprehensive Communication
s* \ COMPREHENSIVE COMNUNICATION IN-HOUSE CONTENT STUDIO ¥ +25 YEAR EXPERIENCE #1 ADVERTISERS IN LATAM 70% CHEAPER & 4X FASTER EXECUTION MULTIMEDIA CAPABILITES FASTER EXECUTION
Slide 27: Diversified Marketing Strategy: In-Store as Media
DIVERSIFIED MARKETING STRATEGY IN-STORE AS MEDIA OWN IN-STORE FURNITURE WORKSHOP 3X CHEAPER & FASTER EXECUTION INCREASING STOPPING POWER AT POS INCREASING COVERSION OPPORTUNITIES
Slide 28: Diversified Marketing Strategy: Gen Expertos
DIVERSIFIED MARKETING STRATEGY GEN EXPERTOS AVAILABILITY, VISIBILITY & RECOMMENDATION ALIGNED INTERESTS WITH PHARMA STAFF INCREASING COVERSION OPPORTUNITIES
Slide 29: Diversified Marketing Strategy: Perfect Store
DIVERSIFIED MARKETING STRATEGY PERFECT STORE Fert Ali-Tnpie] Tnple} WT ri see net Pca Al nple} | Se" (} (ee STANDARIZED EXECUTION STRATEGIES EFFECTIVE KPIs FOR TRADE MARKETING PRODUCT AVAILABILITY CONTROLS EFFICIENT MONITORING
Slide 30: Strong Geographical Footprint
STRONG GEOGRAPHICAL FOOTPRINT UNITED STATES CARICAM Guatemala Honduras El Salvador Belice Costa Rica Panama Nicaragua MEXICO ——, \ ANDEAN CLUSTER oy Colombia Peru Ecuador Bolivia SOUTHERN REGION — Argentina Chile Paraguay Uruguay BRAZIL
Slide 31: Manufacturing & Supply Chain
MANUFACTURING & SUPPLY CHAIN International Finance Corporation WORLD BANK GROUP SUPERIOR PRODUCT QUALITY 4 ENHANCED VALUE EQUATION B_ us$ 100 mm S:YEAR LOAN HIGHER GROSS MARGIN RELIABLE PRODUCT SUPPLY Edge CERTIFICATE fa a Rhee =
Slide 32: MSCI ESG Rating
MSCI ESG RATING | THIRD CONSECUTIVE | RATING IMPROVEMENT Jun-19 Apr-20 May-21 May-23 Feb-24
Slide 33: Growth Projects
Slide 34: 2025: Investing in Future Sales Growth
2025: INVESTING IN FUTURE SALES GROWTH o FF W N 10 Suerox Skincare Haircare [o} Kes Infant nutrition New categories Channels Digital In-store as media Clients Focus on distribution, int. expansion & entering new a segment Asepxia & Cicatricure relaunch Tio Nacho repositioning, Vanart relaunch & int.
Slide 35: Expanding Traditional Channel
EXPANDING TRADITIONAL CHANNEL INCREASING NUMERIC DISTRIBUTION THROUGH STRONGER TRADITIONAL CHANNEL PENETRATION Traditional channel sales Data in US$ Million Excluding US POS $163 Today Bue 830 K POS so $84 $87 3-year target 61 62 53 58 28 40 21M 15 POS | | reachable universe 2013 2014 2015 2016 2017
Slide 36: Securing Supply for Future Growth
SECURING SUPPLY FOR FUTURE GROWTH COMISSIONING NEW SUEROX PRODUCTION LINE Factory Acceptance Test Successfully completed Start of operations On track to start operations in Q@3 2025
Slide 37: Strengthening OTC Innovation Pipeline
STREGTHENING OTC INNOVATION PIPELINE STRONG OTC REGISTRIES MOMENTUM: SUBMITTED REGISTRIES SINCE 2023 NOW APPROACHING APPROVAL STAGE Submitted OTC registries 98 ' 2022 2023 2024 126
Slide 38: Productivity Program
Slide 39: Productivity program progress: MXN 1,800 M
MXN 1,800 M 180 0 1600 MXN 1,018 M 160 0 57% of progress 140 0 1200 120 0 100 0 800 800 600 400 400 200 0 0 2022 2023 2024 2025 2026 2027
Slide 40: SG&A
SG&A MXN $277 million ANNUAL SAVINGS MEDIA More efficient media * More point of sale marketing PAYROLL Headcount optimization Increased automation
Slide 41: Go-to-Market
GO-TO-MARKET PRODUCTIVITY PROJECT MXN $207 million ANNUAL SAVINGS * Effictive price indexing * Optimization of promotions * Efficient comercial terms and conditions * returns and costs serving efficiencies
Slide 42: Raw Materials
RAW MATERIALS PRODUCTIVITY PROJECT MXN $120 million ANNUAL SAVINGS * New tensoactive and fragrance providers * Ingredient substitution * Risk management and cost optimization * Global bidding for APIs ¢ Paracetamol and Naproxeno
Slide 43: Suerox Redesign
SUEROX REDESIGN MXN $100 million ANNUAL SAVINGS * Weight optimization: 30gr > 26.5gr PREFORMS * Cost renegociation SLEEVES * Volume leverage & cost reduction * Cap redesign based on preform specs CAPS * New supplier development ¢ Line efficiencies
Slide 44: Vanart Redesign
VANART REDESIGN PRODUCTIVITY PROJECT MXN $93 million ANNUAL SAVINGS * Packaging reengineering * Standarization * Vertical integration of bottle production * Plastics injection and blowing line * Packaging and raw materials renegociation
Slide 45: Suerox Line
SUEROX LINE PRODUCTIVITY PROJECT MXN $63 million ANNUAL SAVINGS ¢ +96 million bottles per year * Leveraging volumen for better terms and conditions
Slide 46: Logistics Discount-SLOG
LOGISTICS DISCOUNT-SLOG PRODUCTIVITY PROJECT MXN $45 million ANNUAL SAVINGS * Centralized delivery * Route optimization * Higher order for farther deliveries
Slide 47: Suerox Sleeves
SUEROX SLEEVES PRODUCTIVITY PROJECT MXN $30 million ANNUAL SAVINGS ¢ New label equipment * Vertical integration of label production ¢ Economies of scale ¢ Production line efficiencies
Slide 48: Carton Standarization
CARTON STANDARIZATION PRODUCTIVITY PROJECT MXN $25 million ANNUAL SAVINGS * Reduction from 23 to 2 suppliers * Leveraging volumen for lower costs ee skUs * Reduction from 72 to 12 SKUs * Standarizing carton packaging size and thickness across brands
Slide 49: Label Cost Optimization
LABEL COST OPTIMIZATION PRODUCTIVITY PROJECT MXN $25 million ANNUAL SAVINGS SUPPLIERS * Reduction from 16 to 2 suppliers ee scAc * Leveraging volumen for lower costs
Slide 50: Polypropylene Injection
POLYPROPYLENE INJECTION TEATRICAL JARS & CAPS MXN $16 million ANNUAL SAVINGS * Direct feed to Teatrical facial and lanolin lines * Reduced inventories * 20K units per year * Acretive investment * 90% IRR, 0.9 years to payback
Slide 51: Tio Nacho Bottle Blowing
TIO NACHO BOTTLE BLOWING PRODUCTIVITY PROJECT MXN $12 million ANNUAL SAVINGS PWERTICALIZATION | * Vertical integration of bottle production * Integrating size variants in same line [PROcEss ¢ Plastics injection and blowing line
Slide 52: International Logistics
INTERNATIONAL LOGISTICS MXN $11 million ANNUAL SAVINGS ¢ Freight and forwarding optimization BIDDING ° 9 different participants FORWARDERS * 2 Forwarders selected ROUTES * 10 ocean routes quoted
Slide 53: Aluminum Foil
ALUMINUM FOIL PRODUCTIVITY PROJECT MXN $10 million ANNUAL SAVINGS * Bidding process executed ¢ Ink reduction and standarization
Slide 54: Supplemental Package Q1 2025
Slide 55: Q1 2025 key metrics
5.0% +15.8% (Sellout) -2.1% +5.2% (Sellout) 23.8% +149bps 498.7 M +15.4% 0.50 +17.7% 116 d +13 d -6d Payables 2,678 M +62.4% 72% 86% Below target In-line with target Exceeded target
Slide 56: Q1 2025 Portfolio Performance
Q1 2025 PORTFOLIO PERFORMANCE 72% OF SALES GROWING OR MAINTAINING SHARE ISOTONIC BEVERAGES SKINCARE COUGH & COLD e HAIRCARE @ DERMA OTC ANALGESICS GASTRO @ INFANT NUTRITION e BLADES & RAZORS 20%
Slide 57: Q1 2025 Market Performance
Q1 2025 MARKET PERFORMANCE 86% OF SALES GROWING ABOVE INFLATION 20%
Slide 58: Genomma Lab
Genomma Lab.°® GENOMMA LAB
Genomma Lab Intl Sab Ord — Q1 2025 Earnings Presentation on 6ix